Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Therapeutics"
DOI: 10.1097/mjt.0000000000000395
Abstract: Background: Vorapaxar, a novel antiplatelet thrombin PAR-1 inhibitor, is currently approved for post myocardial infarction and peripheral artery disease indications with concomitant use of clopidogrel and/or aspirin. The vorapaxar safety profile was acceptable. However, aside… read more here.
Keywords: adverse association; association vorapaxar; vorapaxar; association ... See more keywords